Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treatment of Graves' ophthalmopathy with diclofenac or simvastatin
2024-517833-42-00Phase 3Authorised
- Sponsor
- Region Skåne
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of diclofenac and simvastatin in Graves' ophthalmopathy (TED) (3 arms), sponsored by Region Skåne. Primary endpoint: Clinical activity score (CAS) and progression to severe Graves' ophthalmopathy at 6 months. Planned start Dec 2024; status: authorised.
02
Drugs
diclofenacsimvastatin
03
Conditions
Graves' ophthalmopathy (TED)
Beyond the preview
Go deeper on 2024-517833-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517833-42-00.